Ignite Creation Date:
2025-12-25 @ 2:04 AM
Ignite Modification Date:
2025-12-26 @ 12:43 AM
Study NCT ID:
NCT01510860
Status:
COMPLETED
Last Update Posted:
2019-05-07
First Post:
2012-01-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis
Sponsor:
Dr. Falk Pharma GmbH
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-11
Start Date Type:
None
Primary Completion Date:
2010-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2010-07
Completion Date Type:
ACTUAL
First Submit Date:
2012-01-12
First Submit QC Date:
None
Study First Post Date:
2012-01-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-05-03
Last Update Post Date:
2019-05-07
Last Update Post Date Type:
ACTUAL